

**PUBLIC ADVISORY**  
**Important Information on Clozaril\***



June 30<sup>th</sup>, 2005

**Subject:**

Reminder: Canadian Requirements for White Blood Cell Monitoring for Patients Taking Clozaril\* (clozapine) Tablets.

Novartis Pharmaceuticals Canada Inc., in consultation with Health Canada, would like to remind you that the blood monitoring requirements related to the use of Clozaril\* (clozapine) tablets have not changed in Canada.

Clozaril\* is indicated in the management of symptoms of treatment-resistant schizophrenia. Due to the significant risk of a blood disorder associated with its use, all patients must have their blood monitored prior to starting and throughout the course of Clozaril\* therapy.

While the schedule of blood monitoring requirements in the United States will be changed, the current requirements in Canada will remain in place. Novartis Pharmaceuticals Canada Inc. does not intend to request changes to the monitoring schedule at this time.

Novartis Pharmaceuticals Canada Inc. reiterates its commitment to the delivery of quality pharmaceutical products and is committed to ensuring the timely dissemination of new information that is important to physicians and patients. If you have questions about your current prescription, please contact your physician or pharmacist.

If you have had a serious or unexpected reaction to Clozaril\* Tablets you may notify either Novartis Pharmaceuticals Canada Inc. or Health Canada as follows:

Novartis Pharmaceuticals Canada Inc.  
385 Bouchard blvd,  
Dorval, (QC) H9S 1A9  
Phone:1-800-363-8883

Any suspected adverse reaction can also be reported to:  
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)  
Marketed Health Products Directorate  
HEALTH CANADA

Address Locator: 0701C

OTTAWA, Ontario, K1A 0K9

Tel: (613) 957-0337 or

Fax: (613) 957-0335

To report an Adverse Reaction (AR), consumers and health professionals may call toll free: Tel: 866 234-2345

Fax: 866 678-6789

[cadtmp@hc-sc.gc.ca](mailto:cadtmp@hc-sc.gc.ca)

The AR Reporting Form ([http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adverse\\_e.html](http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adverse_e.html)) and the AR Guidelines ([http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adr\\_guideline\\_e.html](http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adr_guideline_e.html)) can be found on the Therapeutic Products Directorate web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For media inquiries please contact Jason Jacobs at (514) 633-7872.

\*Clozaril is a registered trademark